Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anya Biopharm's Enterprise Value is NT$1,193.63 Mil.
Anya Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-62.81 Mil. Therefore, Anya Biopharm's EV-to-EBIT ratio for today is -19.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Anya Biopharm's Enterprise Value is NT$1,193.63 Mil.
Anya Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-60.88 Mil. Therefore, Anya Biopharm's EV-to-EBITDA ratio for today is -19.61.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Anya Biopharm's Enterprise Value is NT$1,193.63 Mil.
Anya Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.27 Mil. Therefore, Anya Biopharm's EV-to-Revenue ratio for today is 73.36.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Anya Biopharm's Enterprise Value is NT$1,193.63 Mil.
Anya Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-70.92 Mil. Therefore, Anya Biopharm's EV-to-FCF ratio for today is -16.83.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Anya Biopharm (ROCO:7776) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-62.81 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-60.88 Mil.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.27 Mil.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-69.93 Mil.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-70.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anya Biopharm Enterprise Value Related Terms
Anya Biopharm Enterprise Value Historical Data
* Premium members only.
The historical data trend for Anya Biopharm's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7776 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Anya Biopharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anya Biopharm Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anya Biopharm's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Anya Biopharm's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Anya Biopharm's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$1,193.63 Mil mean?
Anya Biopharm (ROCO:7776) has a Enterprise Value of NT$1,193.63 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anya Biopharm and its competitors.
Is Anya Biopharm's Enterprise Value too high?
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's Enterprise Value compare to VRTX and REGN?
Anya Biopharm's Enterprise Value of NT$1,193.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anya Biopharm and its competitors. Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current Enterprise Value of NT$1,193.63 Mil. The current Enterprise Value is NT$1,193.63 Mil. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current Enterprise Value is NT$1,193.63 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score
Get the complete analysis for ROCO:7776
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7776 has been successfully added to your 